{"created":"2023-06-20T15:49:03.274552+00:00","id":3583,"links":{},"metadata":{"_buckets":{"deposit":"ef17fa82-79d6-49ec-9a73-978344aeef59"},"_deposit":{"created_by":4,"id":"3583","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"3583"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00003583","sets":["2:15:16"]},"author_link":["10456"],"item_5_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"心不全患者においてCYP3A5遺伝子型がトルバプタンの薬物動態に及ぼす影響とそれらのCYP3A活性の内因性マーカーおよび血清ナトリウム値との関係","subitem_alternative_title_language":"ja"}]},"item_5_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-03-16","bibliographicIssueDateType":"Issued"}}]},"item_5_date_granted_17":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2020-03-16"}]},"item_5_degree_grantor_15":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"浜松医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"13802","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_5_degree_name_12":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_5_description_13":{"attribute_name":"学位の区分","attribute_value_mlt":[{"subitem_description":"doctoral","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_5_description_14":{"attribute_name":"学位の分野","attribute_value_mlt":[{"subitem_description":"医学系研究科","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_5_dissertation_number_18":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第840号"}]},"item_5_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"浜松医科大学","subitem_publisher_language":"ja"}]},"item_5_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"星川, 昂平","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"10456","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-09"}],"displaytype":"detail","filename":"DT_840yousi_ron.pdf","filesize":[{"value":"358.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"論文要旨","objectType":"abstract","url":"https://hama-med.repo.nii.ac.jp/record/3583/files/DT_840yousi_ron.pdf"},"version_id":"a78497ba-37cf-4bbc-ac63-e23cd1038224"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-09"}],"displaytype":"detail","filename":"DT_840yousi_sinsa.pdf","filesize":[{"value":"349.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査結果要旨","objectType":"abstract","url":"https://hama-med.repo.nii.ac.jp/record/3583/files/DT_840yousi_sinsa.pdf"},"version_id":"d8646311-3143-48e4-b06e-e6e0c7e49c00"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"thesis","resourceuri":"http://purl.org/coar/resource_type/c_46ec"}]},"item_title":"Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients","subitem_title_language":"en"}]},"item_type_id":"5","owner":"4","path":["16"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-04-09"},"publish_date":"2020-04-09","publish_status":"0","recid":"3583","relation_version_is_last":true,"title":["Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2024-01-17T01:40:59.985516+00:00"}